IR@PKUHSC  > 北京大学深圳医院
学科主题临床医学
Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype
Mi, Yingchang1; Xue, Yanping1; Yu, Wenjuan2; Liu, Shihe1; Zhao, Yaozhong1; Meng, Qingxiang3; Bian, Shougeng1; Wang, Jianxiang1
关键词Leukemia Myeloid Acute Induction Regimen Cytogenetics Prognosis Chemotherapeutic Approaches Neoplasia
刊名LEUKEMIA & LYMPHOMA
2008
DOI10.1080/10428190701836852
49期:3页:524-530
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Hematology
研究领域[WOS]Oncology ; Hematology
关键词[WOS]HIGH-DOSE CYTARABINE ; AML 10 TRIAL ; GROUP-B ; POSTREMISSION THERAPY ; RANDOMIZED-TRIAL ; CANCER ; HOMOHARRINGTONINE ; DAUNORUBICIN ; CYTOGENETICS ; SURVIVAL
英文摘要

One hundred and ninety-six untreated de novo acute myeloid leukemia (AML) patients were treated with homoharringtonine + cytosine arabinoside (HA) based induction therapy composed of three chemotherapeutic drugs (HAD/M, D-daunorubicin-DNR, M-mitozantrone-MTZ) used in our hospital for the past 12 years. The patient population was relatively young (median age 37, oldest patient 67), and patients were excluded if they had prior MDS or prior chemotherapy or radiotherapy. Complete remission (CR) rate, disease free survival (DFS) and overall survival (OS) of the patients were calculated. One hundred and fifty-three patients who had karyotype results were divided into four groups according to Southwestern Oncology Group (SWOG) criteria. Differences of CR rate, DFS and OS of different groups were evaluated. The CR rate of all 196 cases was 153/196 (78.1%), and 95.3% of these were within 1-2 courses. Median DFS of the 153 CR patients was 23.8 (range from 1.0 to 153) months. DFS rates at 3 years and 5 years were 41.1% and 35.9%, respectively. The median OS of 196 patients was 19.3 (0.5-154) months. The probabilities of 3-year and 5-year OS were 31.5% and 29.2%, respectively. CR rate, DFS and OS of the different cytogenetic risk groups were also be analyzed. According to SWOG criteria, patients were classified into favorable, intermediate, adverse and unknown (a group where the meaning of chromosomes are unclear) groups. CR rate, median DFS and OS were 91.9%, 90.8 months and 94.4 months for the favorable group; 86.4%, 22.0 months and 22.8 months for the intermediate group; 59.4%, 9 months and 10.5 months for the adverse group; 76.0%, 22.0 months, 16.1 months for the unknown group, respectively. The differences among the four groups were statistically significant (P=0.001, 0.0033, 0.0001). We conclude that triple-drugs induction regimens based on HA (HAD/M) are highly effective in adult AML in China. Cytogenetics is the important prognostic factor. SWOG karyotype subtyping criteria was appropriate for our patients, the prognosis of the unknown group was similar to that of the intermediate group.

语种英语
WOS记录号WOS:000253513300021
引用统计
被引频次:17[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/57633
专题北京大学深圳医院
作者单位1.Zhejiang Univ, Sch Med, Hangzhou 310027, Peoples R China
2.Beijing Univ, Shenzhen Hosp, Beijing 100871, Peoples R China
3.Chinese Acad Med Sci, Blood Dis Hosp, Inst Hematol,Dept Clin Hematol, Peking Union Med Coll,State Key Lab Expt Hematol, Tianjin 300020, Peoples R China
推荐引用方式
GB/T 7714
Mi, Yingchang,Xue, Yanping,Yu, Wenjuan,et al. Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype[J]. LEUKEMIA & LYMPHOMA,2008,49(3):524-530.
APA Mi, Yingchang.,Xue, Yanping.,Yu, Wenjuan.,Liu, Shihe.,Zhao, Yaozhong.,...&Wang, Jianxiang.(2008).Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype.LEUKEMIA & LYMPHOMA,49(3),524-530.
MLA Mi, Yingchang,et al."Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype".LEUKEMIA & LYMPHOMA 49.3(2008):524-530.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Mi, Yingchang]的文章
[Xue, Yanping]的文章
[Yu, Wenjuan]的文章
百度学术
百度学术中相似的文章
[Mi, Yingchang]的文章
[Xue, Yanping]的文章
[Yu, Wenjuan]的文章
必应学术
必应学术中相似的文章
[Mi, Yingchang]的文章
[Xue, Yanping]的文章
[Yu, Wenjuan]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。